Dosio Launches GLP-1 Shot Tracking App for Ozempic, Wegovy, Mounjaro, and Zepbound Users

Sustainabel announced Dosio, a balanced mobile app that helps people using GLP-1 medication stay organized, understand their routines, and recognize patterns over time with more calm and less guesswork.

For many people, a GLP-1 journey can feel fragmented. Dose schedules, appetite changes, side effects, weight trends, hydration, nutrition, and progress photos often live across notes, spreadsheets, and multiple apps. Dosio was built to give users one place to log injections or oral medication, record dose date, time, dosage, and injection site when relevant, monitor side effects, track weight, calories, protein, and water intake, and review progress photos alongside a calendar of entries.

The product positioning behind Dosio is simple: help people recognize patterns so nothing feels random. Instead of leaning on shame, urgency, or aggressive before-and-after messaging, Dosio is designed as a calm, observational app that helps users bring context to day-to-day changes. Users can follow personalized schedules and reminders, see when their next dose is due, and review charts and daily logs that make it easier to spot relationships between medication timing, symptoms, and routine.

Dosio also supports Apple Health on iOS and Health Connect on Android for read-only import of selected health metrics, helping reduce manual entry while giving users more control over their records. According to the company, imported platform health data remains under the user's control and is not stored on Dosio's servers when connected through these integrations. Users can also export data and, with premium features, generate PDF reports to support conversations with healthcare providers.

Sustainabel created Dosio for adults who want a more private, structured, and non-judgmental way to manage a GLP-1 routine. The app is intended as a personal health and wellness tool for educational purposes and does not provide medical advice, diagnosis, or treatment. With support for multiple languages, secure Apple and Google sign-in, and a design centered on clarity and emotional ease, Dosio aims to give users a better understanding of their own experience, one day at a time.

Sustainabel created Dosio for adults seeking a more private, structured, and non-judgmental way to manage a GLP-1 routine. Designed as a GLP-1 tracker, shot tracker, medication tracker, and side effect tracker, Dosio helps users log injections or oral medication, track weight and health metrics, and stay on schedule with more clarity over time. The app is intended as a personal health and wellness tool for educational purposes only and does not provide medical advice, diagnosis, or treatment. With support for multiple languages, secure Apple and Google sign-in, and a design focused on clarity and emotional ease, Dosio gives users one place to better understand their own GLP-1 experience.

Learn more at https://dosioapp.com.
Download Dosio on the Apple App Store at https://apps.apple.com/us/app/dosio-glp-1-shot-tracker/id6755161636
or on Google Play at https://play.google.com/store/apps/details?id=com.dosio.

Press Contact:
Sustainabel Communications
Polderstraat 34
6533XM Nijmegen
Netherlands
dosio@sustainabel.com

Sustainabel is the company behind Dosio, a mobile health and wellness product focused on helping people understand everyday routines and health-related patterns with more clarity and less guesswork. The diverse company provides next to consumer software also consulting services in the sustainable energy sector.

With Dosio, Sustainabel brings medication logging, schedule management, side-effect tracking, health metrics, progress photos, and data export into one structured mobile experience for people using GLP-1 medication. The company's approach is observational rather than prescriptive: build tools that help users stay organized, notice patterns over time, and have more informed conversations with their healthcare providers.

More information is available at https://dosioapp.com.

This release was published on openPR.